phone Book Now
phone Book Now
Rockyview Health Centre, 1011 Glenmore Trail SW Building #1 Suite 423, Calgary, AB T2V 4R6, Canada
587-353-5061 Book Appointment
Mission
We are passionate about your eyes, and about building long-lasting relationships. Our goal is to ensure your eyes remain healthy throughout your life. We are all about service, love, kindness and a belief in strong community. Through our holistic approach to caring for you and our dedication to learning, we pioneer carefully researched new treatments, technology, and products to help ensure eye health.

Early detection of eye problems is key to successfully preventing vision loss, and begins with an annual eye exam.

Glaucoma affects 250,000 Canadians. It is the second most common cause of vision loss in people over the age of 65. There are several different types of Glaucoma, all characterized by damage to the eye’s optic nerve which connects the retina to the brain. 

Since Glaucoma often has no symptoms, there is no pain and vision loss isn’t immediately noticeable. If left untreated, Glaucoma causes a growing area of vision loss in your peripheral vision.  Coming in for regular eye exams is the single most important thing you can do to prevent it.

Risk Factors

Non-modifiable risk factors are things you can’t change:

  • increased age,
  • female gender,
  • naturally high levels of pressure in the eye,
  • family history of Glaucoma,
  • nearsightedness, 
  • ethnicity;  people of African or Hispanic descent have a greater risk of open angle Glaucoma. Those of Asian or Inuit descent have an increased risk for other types of Glaucoma.

Modifiable risk factors or those that you can change:

  • manage your blood sugar levels and blood pressure,
  • protect your eyes from injuries and infections, 
  • if you have other risk factors, talk to our eye doctors before using antihistamines, antidepressants, dilating eye drops or steroids, or before beginning a weight training program.

Treatment

Treatment usually involves eye drops to lower the pressure in your eye. In some cases, you may need laser or conventional surgery.

Coverage:  as Optometrists, we can monitor patients and initiate treatment, follow-up with patients at risk of developing Glaucoma, and co-manage care with Ophthalmologists when required. Alberta Health Care covers these visits.

Recommendations

Since Glaucoma often has no symptoms, there is no pain and vision loss isn’t immediately noticeable. If left untreated, Glaucoma causes a growing area of vision loss in your peripheral vision.  Coming in for regular eye exams is the single most important thing you can do to prevent it.

Areas We Serve

phone Call NowBook Now

Advanced Myopia Control for Children

Recent randomized controlled clinical trial results presented at the ARVO 2026 Annual Meeting showed promising results for children aged 4–12. Among the 196 children who completed the study, those wearing MiYOSMART iQ showed no average myopia progression after 12 months. The study also found that excessive axial eye growth was reduced to levels below or comparable to those seen in children without refractive errors.

Designed to Help Control Myopia Progression

Myopia, commonly known as short-sightedness, can progress during childhood as the eye grows excessively. Managing myopia earlier in life may help reduce the impact of continued progression and the associated risks of high myopia later in life.

MiYOSMART iQ builds on the established D.I.M.S. Technology used in MiYOSMART lenses and introduces a Triple Enhanced Design (TED). This design incorporates three key enhancements:

  1. Defocus Segments Closer to the Center: The segments are positioned closer to the geometric center of the lens to provide continued exposure to myopic defocus across the near-peripheral retina.
  2. Higher Defocus Power: The lens provides a stronger myopic defocus signal intended to support myopia control.
  3. Extended Treatment Zone: A larger treatment area provides broader coverage of the child’s peripheral visual field, including when larger frames are used.

Clinical Results Across Different Age Groups

The clinical trial included children between 4 and 12 years of age, with results demonstrating myopia-control efficacy across the age groups studied.

For children aged 4–6 years, MiYOSMART iQ demonstrated 65% efficacy in spherical equivalent refractive error (SER) and 44% efficacy in axial length over 12 months. For children aged 7–12 years, the lens demonstrated over 100% efficacy in SER and 94% efficacy in axial length during the same period.

The study also reported a high level of compliance with daily, all-day wear among children across the age groups studied.

Built on Established D.I.M.S. Technology

MiYOSMART iQ represents an evolution of MiYOSMART, a myopia-control lens technology backed by more than 100 peer-reviewed scientific publications. The updated lens design builds on research into how the eye responds to myopic defocus and focuses on delivering a stronger and more consistently positioned defocus signal.

Since its launch in 2018, more than 15 million MiYOSMART spectacle lenses have been purchased by parents across more than 50 countries worldwide.

Supporting Earlier Myopia Management

The clinical findings for MiYOSMART iQ include children as young as four years old, representing an important development in spectacle-lens-based myopia control. Early-onset myopia can progress during a critical period of childhood eye development, making appropriate management an important consideration for children with progressive myopia. MiYOSMART iQ provides an advanced spectacle-lens option for children who require myopia management. An eye care professional can assess your child’s vision and determine whether this type of lens is appropriate for their individual needs.
587-317-2134